DOCSLIB.ORG

Download File

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Systems Biology Approaches to The Study of Neurological Disorders and Somatic Cell Reprogramming William Shin Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2017 c 2016 William Shin All Rights Reserved ABSTRACT Systems Biology Approaches to The Study of Neurological Disorders and Somatic Cell Reprogramming William Shin This thesis describes the development of an systems biology method to study transcriptional pro- grams that are activated during early and late phases of cell-fusion mediated reprogramming, as well as an implementation of systems-level analysis using reverse-engineered regulatory networks to study CNS disorders like Alcohol Addiction, and neurodegenerative disorders like Alzheimer’s Disease (AD), and Parkinson’s Disease (PD). The results will show an unprecedented view into the mechanisms underlying complex processes and diseases, and will demonstrate the predictive power of these methodologies that extended far beyond their original contexts. Table of Contents List of Figures v List of Tables xvi 1 Introduction 1 1.1 Introduction . .1 1.1.1 ARACNe and Mutual Information-based Networks . .2 1.1.2 Interrogation of ARACNe networks : MARINa and VIPER . .3 1.1.3 What Lies Ahead . .5 2 Systems Biology of Heterokaryons 8 2.1 Introduction . .8 2.2 Results . 11 2.2.1 Generation of Heterokaryon Samples . 11 2.2.2 Sequencing and Correction . 11 2.2.3 Data Quality Control . 12 2.2.4 Regulatory Network Analysis of Heterokaryon Data using Virtual Infer- ence of Protein-activity by Enriched Regulon (VIPER) . 13 2.2.5 Singular Value Decomposition (SVD) Results: Heterokaryons . 14 2.2.6 Differentiation and Reprogramming Markers . 16 2.2.7 HSC Reference Dataset . 17 2.2.8 Hierarchical Clustering and VIPER on HSC dataset . 18 i 2.2.9 Comparison to Heterokaryon Results (Fisher’s Exact Test) . 19 2.2.10 Experimental Validation of the MRs controlling reprogramming . 21 2.2.11 Validation of genes that may control the reprogramming of B cells to lineage-committed progenitors . 21 2.2.12 Validation of genes that may control the reprogramming of lineage-committed progenitors to HSC/MPP/MLP like state . 22 2.3 Discussion . 24 2.4 Methods . 26 2.4.1 ARACNe Networks . 26 2.4.2 VIPER . 26 2.4.3 Transcription Factors Classification for Network . 27 2.4.4 HSC Dataset . 27 2.4.5 Transformation for HSC and Heterokaryon dataset for VIPER analysis. 27 2.4.6 Mapping to Human and Mouse Genome and Multi-mapping reads . 28 2.5 Supplementary Information . 29 2.5.1 Performance analysis of B-cell regulatory network, Murine ES and EpiSC regulatory networks . 29 2.5.2 Analysis of B-cell regulatory network, Murine ES and EpiSC regulatory networks on iPS dataset . 32 3 Systems Biology of Alcohol Addiction 67 3.1 Introduction . 67 3.2 Results . 70 3.2.1 Regulatory network assembly . 70 3.2.2 Regulatory network interrogation and validation . 71 3.3 Discussion . 74 3.4 Materials and Methods . 78 3.4.1 Statistical analysis . 78 3.4.2 Gene expression profiles . 78 ii 3.4.3 Cleaner . 78 3.4.4 Transcription Factor classification . 79 3.4.5 Signaling Molecule classification . 79 3.4.6 ARACNe . 79 3.4.7 MARINa and Candidate Selection . 80 3.4.8 Single-Sample MARINa and Activity Correlation Analysis . 81 4 Systems Biology of Alzheimer’s Disease 104 4.1 Introduction . 104 4.2 Results . 107 4.2.1 Selection and assessment of the gene expression profiles dataset . 107 4.2.2 Construction of the human neuronal transcriptional interactome . 107 4.2.3 Identification of candidate Master Regulators using MARINa . 108 4.2.4 Selection of candidate MRs for biochemical validation and results of ex- perimental validation . 109 4.3 Discussion . 111 4.4 Conclusions . 114 4.5 Materials and Methods . 114 4.5.1 Dataset Processing and Normalization . 114 4.5.2 Hierarchical Clustering . 115 4.5.3 ARACNe . 115 4.5.4 MARINa and Candidates Selection . 116 4.5.5 Transcription Factors classification . 117 4.5.6 Specificity-weighted GSEA and Bootstrapping . 117 5 Systems Biology of Parkinson’s Disease 137 5.1 Introduction . 137 5.2 Results . 139 iii 5.2.1 Generation of TRAP transgenic mice for the cell type-specific profiling of DA neurons and Characterization of Dat bacTRAP mice . 139 5.2.2 Translational profiling of midbrain DA neurons in a model of PD . 140 5.2.3 Identification of upstream transcriptional regulators of neurodegeneration . 141 5.2.4 Subtype-specific profiling of SNpc and VTA DA neurons . 142 5.2.5 Validation of novel determinants of SNpc DA neuron degeneration . 143 5.3 Discussion . 145 5.3.1 Brain regulatory network analysis and identification of MRs . 145 5.3.2 Validation of novel drivers of DA degeneration . 147 5.4 Methods . 148 5.4.1 TRAPseq and gene expression analysis . 148 5.4.2 Regulatory networks assembly . 149 5.4.3 MR analyses on mouse translatomes . 149 5.4.4 MR analysis on PD expression signatures . 150 5.4.5 GSEA analysis . 151 6 Discussion 156 6.1 Discussion . 156 Bibliography 158 iv List of Figures 2.1 Flow chart showing the generation of heterokaryon samples through cell-cell fu- sion and subsequent FACS sorting of fused-cells and paired-end sequencing. 34 2.2 Comparison of replicates for human gene expression during cell-fusion mediated reprogramming over five days. Spearman correlation is shown. Replicate 1 is shown on the x-axis and Replicate 2 is shown on the y-axis. 35 2.3 Expression of a representative set of human pluripotency markers in the heterokaryon samples during reprogramming. The results show the raw-count of each gene nor- malized to GAPDH . 36 2.4 Hierarchical clustering of heterokaryons samples show strong separation according to time point. Plotting was performed using the complete agglomeration method using the expression values of the top-2000 genes with the highest variance across all the samples. 37 2.5 MAplot showing differential expression of human genes after cell-cell fusion with murine ES cell. log2 fold-change of normalized counts are plotted on the y-axis and average log expression values are shown on the x-axis. Blue-dashed line indicates fold-change of 1. Genes displaying a significant (pval < 0.01) change in expression are shown in red. 38 v 2.6 MAplot showing differential expression of mouse genes in an ES cell after cell- cell fusion with a human b-cell. log2 fold-change of normalized counts are plotted on the y-axis and average normalized counts are shown on the x-axis. Blue-dashed line indicates fold-change of 1. Genes displaying a significant (pval < 0.01) change in expression are shown in red. 39 2.7 Heatmap of VIPER activity for significant heterokaryon MR candidates. Heatmap shows NES values of 633 TFs that were significant (FDR < 0.01) in the het- erokaryon samples. NES values were calculated using the VIPER algorithm, com- paring the each heterokaryon sample against the unfused B-cell. Positive NES val- ues are shown in red, and negative NES values are shown in blue. 40 2.8 Plot showing total variance of VIPER activity in the heterokaryon dataset ex- plained by each eigengene after SVD analysis. Eigengenes are plotted on the y- axis, and the proportion of variance is plotted on the x-axis. 41 2.9 Plot showing the Eigengene levels across the sample timepoints for the top-2 Eigengenes of the heterokaryon dataset. The feature levels show a bimodal pat- tern across timepoints after cell-cell fusion. 42 2.10 VIPER-predicted activity and differential expression of a representative set of hu- man Bcell, pluripotency, and HSC markers during reprogramming. VIPER-predicted activities are represented by Normalized Enrichment Sores (NES), and were cal- culated using the VIPER algorithm, comparing the heterokaryon samples of each time point (either 4h, 12h, 48h, 120h) against the unfused B-cell. Positive NES values are shown in red, and negative NES values are shown in blue. Differential expression was calculated using EdgeR, which uses a negative-binomial distribu- tion to calculate the variance of reads. Log2FC values are shown, with positive values shown in orange, and negative values shown in purple. A and B show the results for Bcell markers, C and D show the results for pluripotency markers, and E and F show the results for HSC markers. 43 vi 2.11 Hierarchical model of hematopoietic development, adapted from Laurenti et al. and Doulatov et al. [Laurenti et al., 2013; Doulatov et al., 2010] .......... 44 2.12 Hierarchical clustering of HSC samples shows significant variations between cells of the same type. Plotting was performed using the complete agglomeration method, with the expression values of the top-2000 genes with the highest variance across all the samples. 45 2.13 Heatmap of predicted activity for significant HSC MR candidates. Heatmap shows NES values of 445 TFs that were significant (FDR < 0.01) in each sample com- pared to unfused B-cell samples. NES values were calculated using the VIPER algorithm, comparing the samples of each cell-type against the unfused B-cell. Positive NES values are shown in red, and negative NES values are shown in blue. 46 2.14 Results of transcriptional similarity between heterokaryons and celltypes in the HSC dataset. Fisher’s Exact Test (FET) was used to calculate the significance of overlap between candidate TFs whose activities were both significant (FDR < 0.05) and positive in each celltype. {log10 of the p-values of the overlap are shown. 47 2.15 Heatmap showing the clustering of the TFS that were part of the early and late transcriptional programs in the Heterokaryons.
Recommended publications
  • Analysis of Trans Esnps Infers Regulatory Network Architecture

    Analysis of Trans Esnps Infers Regulatory Network Architecture

    Analysis of trans eSNPs infers regulatory network architecture Anat Kreimer Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2014 © 2014 Anat Kreimer All rights reserved ABSTRACT Analysis of trans eSNPs infers regulatory network architecture Anat Kreimer eSNPs are genetic variants associated with transcript expression levels. The characteristics of such variants highlight their importance and present a unique opportunity for studying gene regulation. eSNPs affect most genes and their cell type specificity can shed light on different processes that are activated in each cell. They can identify functional variants by connecting SNPs that are implicated in disease to a molecular mechanism. Examining eSNPs that are associated with distal genes can provide insights regarding the inference of regulatory networks but also presents challenges due to the high statistical burden of multiple testing. Such association studies allow: simultaneous investigation of many gene expression phenotypes without assuming any prior knowledge and identification of unknown regulators of gene expression while uncovering directionality. This thesis will focus on such distal eSNPs to map regulatory interactions between different loci and expose the architecture of the regulatory network defined by such interactions. We develop novel computational approaches and apply them to genetics-genomics data in human. We go beyond pairwise interactions to define network motifs, including regulatory modules and bi-fan structures, showing them to be prevalent in real data and exposing distinct attributes of such arrangements. We project eSNP associations onto a protein-protein interaction network to expose topological properties of eSNPs and their targets and highlight different modes of distal regulation.
  • Title a New Centrosomal Protein Regulates Neurogenesis By

    Title a New Centrosomal Protein Regulates Neurogenesis By

    Title A new centrosomal protein regulates neurogenesis by microtubule organization Authors: Germán Camargo Ortega1-3†, Sven Falk1,2†, Pia A. Johansson1,2†, Elise Peyre4, Sanjeeb Kumar Sahu5, Loïc Broic4, Camino De Juan Romero6, Kalina Draganova1,2, Stanislav Vinopal7, Kaviya Chinnappa1‡, Anna Gavranovic1, Tugay Karakaya1, Juliane Merl-Pham8, Arie Geerlof9, Regina Feederle10,11, Wei Shao12,13, Song-Hai Shi12,13, Stefanie M. Hauck8, Frank Bradke7, Victor Borrell6, Vijay K. Tiwari§, Wieland B. Huttner14, Michaela Wilsch- Bräuninger14, Laurent Nguyen4 and Magdalena Götz1,2,11* Affiliations: 1. Institute of Stem Cell Research, Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany. 2. Physiological Genomics, Biomedical Center, Ludwig-Maximilian University Munich, Germany. 3. Graduate School of Systemic Neurosciences, Biocenter, Ludwig-Maximilian University Munich, Germany. 4. GIGA-Neurosciences, Molecular regulation of neurogenesis, University of Liège, Belgium 5. Institute of Molecular Biology (IMB), Mainz, Germany. 6. Instituto de Neurociencias, Consejo Superior de Investigaciones Científicas and Universidad Miguel Hernández, Sant Joan d’Alacant, Spain. 7. Laboratory for Axon Growth and Regeneration, German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany. 8. Research Unit Protein Science, Helmholtz Centre Munich, German Research Center for Environmental Health, Munich, Germany. 9. Protein Expression and Purification Facility, Institute of Structural Biology, Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany. 10. Institute for Diabetes and Obesity, Monoclonal Antibody Core Facility, Helmholtz Center Munich, German Research Center for Environmental Health, Munich, Germany. 11. SYNERGY, Excellence Cluster of Systems Neurology, Biomedical Center, Ludwig- Maximilian University Munich, Germany. 12. Developmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, USA 13.
  • Molecular Mechanism of ACAD9 in Mitochondrial Respiratory Complex 1 Assembly

    Molecular Mechanism of ACAD9 in Mitochondrial Respiratory Complex 1 Assembly

    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.07.425795; this version posted January 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Molecular mechanism of ACAD9 in mitochondrial respiratory complex 1 assembly Chuanwu Xia1, Baoying Lou1, Zhuji Fu1, Al-Walid Mohsen2, Jerry Vockley2, and Jung-Ja P. Kim1 1Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, USA 2Department of Pediatrics, University of Pittsburgh School of Medicine, University of Pittsburgh, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA 15224, USA Abstract ACAD9 belongs to the acyl-CoA dehydrogenase family, which catalyzes the α-β dehydrogenation of fatty acyl-CoA thioesters. Thus, it is involved in fatty acid β-oxidation (FAO). However, it is now known that the primary function of ACAD9 is as an essential chaperone for mitochondrial respiratory complex 1 assembly. ACAD9 interacts with ECSIT and NDUFAF1, forming the mitochondrial complex 1 assembly (MCIA) complex. Although the role of MCIA in the complex 1 assembly pathway is well studied, little is known about the molecular mechanism of the interactions among these three assembly factors. Our current studies reveal that when ECSIT interacts with ACAD9, the flavoenzyme loses the FAD cofactor and consequently loses its FAO activity, demonstrating that the two roles of ACAD9 are not compatible. ACAD9 binds to the carboxy-terminal half (C-ECSIT), and NDUFAF1 binds to the amino-terminal half of ECSIT. Although the binary complex of ACAD9 with ECSIT or with C-ECSIT is unstable and aggregates easily, the ternary complex of ACAD9-ECSIT-NDUFAF1 (i.e., the MCIA complex) is soluble and extremely stable.
  • CHD4/Nurd Complex Regulates Complement Gene Expression And

    CHD4/Nurd Complex Regulates Complement Gene Expression And

    Shao et al. Clinical Epigenetics (2020) 12:31 https://doi.org/10.1186/s13148-020-00827-3 RESEARCH Open Access CHD4/NuRD complex regulates complement gene expression and correlates with CD8 T cell infiltration in human hepatocellular carcinoma Simin Shao1†, Haowei Cao1†, Zhongkun Wang1, Dongmei Zhou2, Chaoshen Wu1, Shu Wang1, Dian Xia1 and Daoyong Zhang1* Abstract Backgrounds: The NuRD (Nucleosome Remodeling and Deacetylation) complex is a repressive complex in gene transcription by modulating chromatin accessibility of target genes to transcription factors and RNA polymerase II. Although individual subunits of the complex have been implicated in many other cancer types, the complex’s role in human hepatocellular carcinoma (HCC) is not fully understood. More importantly, the NuRD complex has not yet been investigated as a whole in cancers. Methods: We analyzed the expression of the NuRD complex in HCC and evaluated the prognostic value of NuRD complex expression in HCC using the RNA-seq data obtained from the TCGA project. We examined the effect of CHD4 knockdown on HCC cell proliferation, apoptosis, migration, invasion, epithelial-mesenchymal transition, colony-forming ability, and on complement gene expression. We also performed bioinformatic analyses to investigate the correlation between the NuRD complex expression and immune infiltration. Results: We found that nine subunits, out of 14 subunits of the NuRD complex examined, were significantly overexpressed in HCC, and their expression levels were positively correlated with cancer progression. More importantly, our data also demonstrated that these subunits tended to be overexpressed as a whole in HCC. Subsequent studies demonstrated that knockdown of CHD4 in HCC cells inhibits cell proliferation, migration, invasion, and colony-forming ability and promotes apoptosis of HCC cells, indicating that the CHD4/NuRD complex plays oncogenic roles in HCC.
  • Transcriptional Targets of Hepatocyte Growth Factor Signaling and Ki-Ras Oncogene Activation in Colorectal Cancer

    Transcriptional Targets of Hepatocyte Growth Factor Signaling and Ki-Ras Oncogene Activation in Colorectal Cancer

    Oncogene (2006) 25, 91–102 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc ORIGINAL ARTICLE Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer IM Seiden-Long1,2, KR Brown1,2, W Shih1, DA Wigle3, N Radulovich1, I Jurisica1,2,4 and M-S Tsao1,2,5 1Ontario Cancer Institute/Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada; 2Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada; 3Department of Surgery, University of Toronto, Toronto, Ontario, Canada; 4Department of Computer Science, University of Toronto, Toronto, Ontario, Canada and 5Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada Both Ki-ras mutation and hepatocyte growth factor Introduction (HGF) receptor Met overexpression occur at high frequency in colon cancer. This study investigates the Colorectal carcinogenesis is characterized by a well- transcriptional changes induced by Ki-ras oncogene and delineated series of genetic mutations and aberrant gene HGF/Met signaling activation in colon cancer cell lines in expression events (Fearon and Vogelstein, 1990). Ki-ras vitro and in vivo. The model system used in these studies oncogene activation and the overexpression of growth included the DLD-1 colon cancer cell line with a mutated factor receptors on the cell surface have been shown to Ki-ras allele, and the DKO-4 cell line generated from play important rolesin colon cancer progression DLD-1, with its mutant Ki-ras allele inactivated by (Shirasawa et al., 1993; Fazekas et al., 2000). Ki-ras is targeted disruption.
  • Cyclin D1 Is a Direct Transcriptional Target of GATA3 in Neuroblastoma Tumor Cells

    Cyclin D1 Is a Direct Transcriptional Target of GATA3 in Neuroblastoma Tumor Cells

    Oncogene (2010) 29, 2739–2745 & 2010 Macmillan Publishers Limited All rights reserved 0950-9232/10 $32.00 www.nature.com/onc SHORT COMMUNICATION Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells JJ Molenaar1,2, ME Ebus1, J Koster1, E Santo1, D Geerts1, R Versteeg1 and HN Caron2 1Department of Human Genetics, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands and 2Department of Pediatric Oncology, Emma Kinderziekenhuis, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands Almost all neuroblastoma tumors express excess levels of 2000). Several checkpoints normally prevent premature Cyclin D1 (CCND1) compared to normal tissues and cell-cycle progression and cell division. The crucial G1 other tumor types. Only a small percentage of these entry point is controlled by the D-type Cyclins that can neuroblastoma tumors have high-level amplification of the activate CDK4/6 that in turn phosphorylate the pRb Cyclin D1 gene. The other neuroblastoma tumors have protein. This results in a release of the E2F transcription equally high Cyclin D1 expression without amplification. factor that causes transcriptional upregulation of Silencing of Cyclin D1 expression was previously found to numerous genes involved in further progression of the trigger differentiation of neuroblastoma cells. Over- cell cycle (Sherr, 1996). expression of Cyclin D1 is therefore one of the most Neuroblastomas are embryonal tumors that originate frequent mechanisms with a postulated function in neuro- from precursor cells of the sympathetic nervous system. blastoma pathogenesis. The cause for the Cyclin D1 This tumor has a very poor prognosis and despite the overexpression is unknown.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • 1 Supporting Information for a Microrna Network Regulates

    1 Supporting Information for a Microrna Network Regulates

    Supporting Information for A microRNA Network Regulates Expression and Biosynthesis of CFTR and CFTR-ΔF508 Shyam Ramachandrana,b, Philip H. Karpc, Peng Jiangc, Lynda S. Ostedgaardc, Amy E. Walza, John T. Fishere, Shaf Keshavjeeh, Kim A. Lennoxi, Ashley M. Jacobii, Scott D. Rosei, Mark A. Behlkei, Michael J. Welshb,c,d,g, Yi Xingb,c,f, Paul B. McCray Jr.a,b,c Author Affiliations: Department of Pediatricsa, Interdisciplinary Program in Geneticsb, Departments of Internal Medicinec, Molecular Physiology and Biophysicsd, Anatomy and Cell Biologye, Biomedical Engineeringf, Howard Hughes Medical Instituteg, Carver College of Medicine, University of Iowa, Iowa City, IA-52242 Division of Thoracic Surgeryh, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada-M5G 2C4 Integrated DNA Technologiesi, Coralville, IA-52241 To whom correspondence should be addressed: Email: [email protected] (M.J.W.); yi- [email protected] (Y.X.); Email: [email protected] (P.B.M.) This PDF file includes: Materials and Methods References Fig. S1. miR-138 regulates SIN3A in a dose-dependent and site-specific manner. Fig. S2. miR-138 regulates endogenous SIN3A protein expression. Fig. S3. miR-138 regulates endogenous CFTR protein expression in Calu-3 cells. Fig. S4. miR-138 regulates endogenous CFTR protein expression in primary human airway epithelia. Fig. S5. miR-138 regulates CFTR expression in HeLa cells. Fig. S6. miR-138 regulates CFTR expression in HEK293T cells. Fig. S7. HeLa cells exhibit CFTR channel activity. Fig. S8. miR-138 improves CFTR processing. Fig. S9. miR-138 improves CFTR-ΔF508 processing. Fig. S10. SIN3A inhibition yields partial rescue of Cl- transport in CF epithelia.
  • UBE2N Antibody (N-Term) Blocking Peptide Synthetic Peptide Catalog # Bp13846a

    UBE2N Antibody (N-Term) Blocking Peptide Synthetic Peptide Catalog # Bp13846a

    10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 UBE2N Antibody (N-term) Blocking peptide Synthetic peptide Catalog # BP13846a Specification UBE2N Antibody (N-term) Blocking UBE2N Antibody (N-term) Blocking peptide - peptide - Background Product Information The modification of proteins with ubiquitin is Primary Accession P61088 animportant cellular mechanism for targeting abnormal or short-livedproteins for degradation. Ubiquitination involves at least UBE2N Antibody (N-term) Blocking peptide - Additional Information threeclasses of enzymes: ubiquitin-activating enzymes, or E1s,ubiquitin-conjugating enzymes, or E2s, and ubiquitin-proteinligases, Gene ID 7334 or E3s. This gene encodes a member of the E2ubiquitin-conjugating enzyme family. Other Names Studies in mouse suggest thatthis protein plays Ubiquitin-conjugating enzyme E2 N, a role in DNA postreplication repair. Bendless-like ubiquitin-conjugating enzyme, [providedby RefSeq]. Ubc13, UbcH13, Ubiquitin carrier protein N, Ubiquitin-protein ligase N, UBE2N, BLU UBE2N Antibody (N-term) Blocking Target/Specificity peptide - References The synthetic peptide sequence used to generate the antibody AP13846a was Zhao, J., et al. BMC Med. Genet. 11, 96 (2010) selected from the N-term region of UBE2N. :Markson, G., et al. Genome Res. A 10 to 100 fold molar excess to antibody is 19(10):1905-1911(2009)Topisirovic, I., et al. recommended. Precise conditions should be Proc. Natl. Acad. Sci. U.S.A. optimized for a particular assay. 106(31):12676-12681(2009)Yin, Q., et al. Nat. Struct. Mol. Biol. 16(6):658-666(2009)van Wijk, Format S.J., et al. Mol. Syst. Biol. 5, 295 (2009) : Peptides are lyophilized in a solid powder format.
  • CGGBP1 (NM 003663) Human Recombinant Protein – TP308653

    CGGBP1 (NM 003663) Human Recombinant Protein – TP308653

    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP308653 CGGBP1 (NM_003663) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human CGG triplet repeat binding protein 1 (CGGBP1), transcript variant 2 Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 18.6 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_003654 Locus ID: 8545 UniProt ID: Q9UFW8 RefSeq Size: 4506 Cytogenetics: 3p11.1 RefSeq ORF: 501 Synonyms: CGGBP; p20-CGGBP This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 CGGBP1 (NM_003663) Human Recombinant Protein – TP308653 Summary: This gene encodes a CGG repeat-binding protein that primarily localizes to the nucleus. CGG trinucleotide repeats are implicated in many disorders as they often act as transcription- and translation-regulatory elements, can produce hairpin structures which cause DNA replication errors, and form regions prone to chromosomal breakage.
  • Ubiquitin and Ubiquitin-Like Proteins Are Essential Regulators of DNA Damage Bypass

    Ubiquitin and Ubiquitin-Like Proteins Are Essential Regulators of DNA Damage Bypass

    cancers Review Ubiquitin and Ubiquitin-Like Proteins Are Essential Regulators of DNA Damage Bypass Nicole A. Wilkinson y, Katherine S. Mnuskin y, Nicholas W. Ashton * and Roger Woodgate * Laboratory of Genomic Integrity, National Institute of Child Health and Human Development, National Institutes of Health, 9800 Medical Center Drive, Rockville, MD 20850, USA; [email protected] (N.A.W.); [email protected] (K.S.M.) * Correspondence: [email protected] (N.W.A.); [email protected] (R.W.); Tel.: +1-301-435-1115 (N.W.A.); +1-301-435-0740 (R.W.) Co-first authors. y Received: 29 August 2020; Accepted: 29 September 2020; Published: 2 October 2020 Simple Summary: Ubiquitin and ubiquitin-like proteins are conjugated to many other proteins within the cell, to regulate their stability, localization, and activity. These modifications are essential for normal cellular function and the disruption of these processes contributes to numerous cancer types. In this review, we discuss how ubiquitin and ubiquitin-like proteins regulate the specialized replication pathways of DNA damage bypass, as well as how the disruption of these processes can contribute to cancer development. We also discuss how cancer cell survival relies on DNA damage bypass, and how targeting the regulation of these pathways by ubiquitin and ubiquitin-like proteins might be an effective strategy in anti-cancer therapies. Abstract: Many endogenous and exogenous factors can induce genomic instability in human cells, in the form of DNA damage and mutations, that predispose them to cancer development. Normal cells rely on DNA damage bypass pathways such as translesion synthesis (TLS) and template switching (TS) to replicate past lesions that might otherwise result in prolonged replication stress and lethal double-strand breaks (DSBs).
  • Supplementary Materials

    Supplementary Materials

    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine